Logo

SCNX

Scienture Holdings, Inc.

SCNX

Scienture Holdings, Inc. • NASDAQ
$0.60 ▲ 1.22% (+0.01)
Market Cap $9.22 M
52w High $8.72
52w Low $0.46
Dividend Yield 1.50%
P/E 0.8
Volume 347.53K
Outstanding Shares 15.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $590.05K ▲ $4.182M ▼ $-3.607M ▲ -611.365% ▼ $-0.19 ▲ $-1.797M ▲
Q2-2025 $0 ▼ $5.142M ▲ $-6.721M ▼ 0% ▲ $-0.475 ▼ $-6.052M ▼
Q1-2025 $10.258K ▼ $3.572M ▼ $-3.064M ▲ -29.869K% ▼ $-0.33 ▲ $-2.378M ▲
Q4-2024 $53.083K ▼ $4.217M ▲ $-7.163M ▼ -13.493K% ▼ $-0.82 ▲ $-6.308M ▼
Q3-2024 $64.861K $3.502M $-3.184M -4.908K% $-1.34 $-2.944M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $355.692K ▲ $104.83M ▲ $22.161M ▼ $82.67M ▲
Q2-2025 $15.391K ▼ $104.295M ▼ $26.434M ▲ $77.86M ▼
Q1-2025 $2.05M ▲ $106.359M ▲ $25.196M ▼ $81.163M ▲
Q4-2024 $308.096K ▼ $104.854M ▲ $25.782M ▲ $79.072M ▼
Q3-2024 $579.103K $94.26M $9.128M $85.132M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.607M ▲ $-3.214M ▼ $0 $3.554M ▲ $340.301K ▲ $-3.214M ▼
Q2-2025 $-6.721M ▼ $-2.034M ▲ $0 $0 ▼ $-2.034M ▼ $-2.034M ▲
Q1-2025 $-3.064M ▲ $-2.956M ▼ $0 $4.698M ▲ $1.742M ▲ $-2.956M ▼
Q4-2024 $-6.803M ▼ $-2.909M ▲ $0 ▼ $2.79M ▲ $-271.007K ▲ $-2.909M ▲
Q3-2024 $-3.184M $-5.388M $120.976K $-1.874M $-7.141M $-5.4M

Five-Year Company Overview

Income Statement

Income Statement The income statement reads like that of a company still in the very early stages of its new business model. Revenue over the past several years has been essentially negligible, suggesting that the current specialty pharma strategy has not yet translated into meaningful sales in the reported period. Operating results have generally been loss‑making, consistent with a company spending on development and overhead without a mature product base. The recent swing to a positive bottom line looks more like an accounting or one‑time effect than a sign of a healthy, revenue‑driven business. Earnings per share have been extremely volatile, likely influenced by the reverse stock split and the very small base of operations, which makes any change look large on a per‑share basis. Overall, the income statement shows a business still in transition and not yet supported by recurring product revenue.

Balance Sheet

Balance Sheet The balance sheet is very small in scale, which is typical of a micro‑cap or recently restructured company. Total assets and equity are modest, indicating a limited cushion to absorb setbacks. Cash levels appear thin, and while debt does not look burdensome, the low absolute level of resources means financial flexibility is constrained. The recent improvement in equity is a positive sign, but it starts from a low base, so there is not yet a deep capital buffer. In practical terms, the company looks lean and lightly geared, but also financially fragile, with a likely ongoing need for outside funding as it invests in product launches and its pipeline.

Cash Flow

Cash Flow Cash flow data reinforces the picture of a development‑stage company. Operating cash flow has been modestly negative, reflecting spending on overhead and early commercialization without meaningful incoming cash from product sales. Free cash flow is also negative, though capital spending appears minimal, which is typical for an asset‑light, formulation‑focused pharma model. The lack of internally generated cash suggests the business is not yet self‑funding and is reliant on external financing or one‑off transactions to cover its burn. Future stability will hinge on whether new products can shift the cash flow profile from small outflows to recurring inflows.

Competitive Edge

Competitive Edge Scienture’s competitive position is built around focused niches rather than scale. Its main strengths are first‑in‑class or best‑in‑class formulations in very specific use cases: a ready‑to‑use liquid version of a widely used blood pressure drug for patients who cannot swallow pills, and a high‑strength naloxone nasal spray aimed at severe opioid overdoses. Patent protection on Arbli and its status as the only approved product of its kind give it a degree of insulation from direct competition in that segment. The company’s background in pharmaceutical distribution technology could also support efficient market access. On the other hand, Scienture is small and operates in markets where large pharmaceutical and generic companies are active. Its success will depend on execution in commercialization, gaining and keeping reimbursement coverage, physician and patient adoption, and defending its niche against future entrants. The moat is promising but still unproven at scale.

Innovation and R&D

Innovation and R&D Innovation is the core of Scienture’s story. The company focuses on reformulating and repurposing existing drugs via a regulatory pathway that can be faster and less costly than developing entirely new molecules. Arbli and REZENOPY are practical examples of this strategy: they take known active ingredients and package them in more patient‑friendly or clinically targeted forms. Beyond the launched or near‑launched products, the pipeline includes a self‑injection migraine therapy, a long‑acting non‑opioid pain treatment, and a planned cardiovascular biosimilar for hospital use. These projects target sizable markets but face intense competition and significant clinical, regulatory, and commercial risk. The long timelines, especially for the biosimilar, mean that the payoff from R&D is uncertain and likely years away. Overall, the innovation strategy is clear and differentiated, but the actual value will depend on successful trials, approvals, and real‑world adoption.

Summary

Scienture today looks like a company midway through a major transformation. The historical financials show a tiny, loss‑making operation with almost no revenue, a small balance sheet, and ongoing cash burn—typical of an early‑stage specialty pharma business that has only recently begun to commercialize products. The strategic pivot, centered on Arbli and REZENOPY, gives it a clearer identity and some defensible niches supported by patents and regulatory positioning. At the same time, its small scale, limited financial resources, and dependence on a handful of products and pipeline assets create a high‑uncertainty profile. The key variables to watch are how quickly new products gain traction in the market, how effectively the company manages its cash needs, and whether its pipeline can progress without major setbacks. In essence, this is a high‑risk, high‑dependence story where execution on a few critical products will largely determine future financial health.

NEWS

November 13, 2025 · 8:05 AM UTC

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Read more

November 4, 2025 · 8:05 AM UTC

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Read more

October 23, 2025 · 8:05 AM UTC

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Read more

October 16, 2025 · 9:00 AM UTC

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Read more

October 13, 2025 · 8:00 AM UTC

Wellgistics Health Announces Executive Management and Board Changes

Read more